Glaukos (GKOS) said Thursday it launched Epioxa for the treatment of keratoconus, a rare eye disease.

The drug is commercially available through direct ordering and the company's specialty pharmaceutical distribution network, Glaukos said.

Glaukos shares were down 0.9% in Thursday premarket trading.